Lactococcus lactis harbouring Ara h 2.02 alleviates allergen‐specific Th2‐associated responses in sensitized mice
Aim To study the prophylactic effect of recombinant Lactococcus lactis (rLl) harbouring Ara h 2.02 peanut allergen, in sensitized and challenged mice. Methods and Results Ara h 2.02 cDNA was cloned into pNZ8048 for heterologous expression in L. lactis. The purified recombinant allergen showed IgE bi...
Saved in:
Published in | Journal of applied microbiology Vol. 128; no. 3; pp. 862 - 874 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.03.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Aim
To study the prophylactic effect of recombinant Lactococcus lactis (rLl) harbouring Ara h 2.02 peanut allergen, in sensitized and challenged mice.
Methods and Results
Ara h 2.02 cDNA was cloned into pNZ8048 for heterologous expression in L. lactis. The purified recombinant allergen showed IgE binding comparable with native Ara h 2. Balb/c mice were fed with either recombinant (rLl), nonrecombinant L. lactis (Ll) or NaHCO3 (Sham) prior to sensitization and challenged with rAra h 2.02, whereas the baseline group was only fed with Ll. Allergen‐specific immunoglobulin and splenocyte cytokines responses were determined for each mouse. Mice fed with either Ll or rLl showed significant alleviation of IgE and IgG1 compared to the Sham group. Despite no significant decrease in Th2 (IL‐4, IL‐13, IL‐6) or increase in Th1 (IFN‐γ) cytokines, both groups showed lower IL‐10 level, while the IL‐4 : IFN‐γ ratio was significantly lower for rLl compared to Ll group.
Conclusions
Oral administration of rLl harbouring Ara h 2.02 demonstrated alleviation of Th2‐associated responses in allergen‐challenged mice and a possible added allergen‐specific prophylactic effect.
Significance and Impact of the Study
Ara h 2.02 coupled with the intrinsic properties of probiotic L. lactis as a delivery vehicle can be explored for the development of a commercially scalable vaccine. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1364-5072 1365-2672 |
DOI: | 10.1111/jam.14524 |